Cargando…

The dimensionality of fatigue in Parkinson’s disease

BACKGROUND: Fatigue is a common problem among individuals with Parkinson’s disease (PD). It may occur before the overt symptoms of bradykinesia, rigidity and tremor. Little is understood about how to measure fatigue in PD. Here we determined the dimensionality of the constructs of fatigue. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Chong, Raymond, Albor, Lauren, Wakade, Chandramohan, Morgan, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6040062/
https://www.ncbi.nlm.nih.gov/pubmed/29996887
http://dx.doi.org/10.1186/s12967-018-1554-z
_version_ 1783338788036018176
author Chong, Raymond
Albor, Lauren
Wakade, Chandramohan
Morgan, John
author_facet Chong, Raymond
Albor, Lauren
Wakade, Chandramohan
Morgan, John
author_sort Chong, Raymond
collection PubMed
description BACKGROUND: Fatigue is a common problem among individuals with Parkinson’s disease (PD). It may occur before the overt symptoms of bradykinesia, rigidity and tremor. Little is understood about how to measure fatigue in PD. Here we determined the dimensionality of the constructs of fatigue. METHODS: Four recommended scales, the Fatigue Severity Scale, Functional Assessment of Chronic Illness Therapy-Fatigue, Parkinson Fatigue Scale and Visual Analog Fatigue Scale (VAFS) were tested against quality of life measures including cognition, depression, sleep, life orientation, physical activity and PD symptoms in 22 PD subjects and 15 caregivers. RESULTS: Fatigue was associated with many quality of life variables, with the PDQ-39 summary index showing the strongest association. PD subjects agreed more strongly than caregivers that they experienced higher levels of fatigue. 27% of PD subjects rated fatigue as one of their top three most bothersome symptoms. The constructs of fatigue was captured within one dimension which explained 67% of the total variance, of which the VAFS showed the highest internal consistency. The highest likelihood ratio gave a cut-off score of < 5.5 on the VAFS. The change in scores required to produce a perceptible difference or is grossly observable ranged between 1.4 and 2.2 points respectively. CONCLUSION: The potential utility of a single measure such as the VAFS in PD that is reliably correlated with quality of life is consistent with the pursuit to develop clinical tests and measurements that are accessible, easy to use and universally interpretable across health science disciplines.
format Online
Article
Text
id pubmed-6040062
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-60400622018-07-13 The dimensionality of fatigue in Parkinson’s disease Chong, Raymond Albor, Lauren Wakade, Chandramohan Morgan, John J Transl Med Research BACKGROUND: Fatigue is a common problem among individuals with Parkinson’s disease (PD). It may occur before the overt symptoms of bradykinesia, rigidity and tremor. Little is understood about how to measure fatigue in PD. Here we determined the dimensionality of the constructs of fatigue. METHODS: Four recommended scales, the Fatigue Severity Scale, Functional Assessment of Chronic Illness Therapy-Fatigue, Parkinson Fatigue Scale and Visual Analog Fatigue Scale (VAFS) were tested against quality of life measures including cognition, depression, sleep, life orientation, physical activity and PD symptoms in 22 PD subjects and 15 caregivers. RESULTS: Fatigue was associated with many quality of life variables, with the PDQ-39 summary index showing the strongest association. PD subjects agreed more strongly than caregivers that they experienced higher levels of fatigue. 27% of PD subjects rated fatigue as one of their top three most bothersome symptoms. The constructs of fatigue was captured within one dimension which explained 67% of the total variance, of which the VAFS showed the highest internal consistency. The highest likelihood ratio gave a cut-off score of < 5.5 on the VAFS. The change in scores required to produce a perceptible difference or is grossly observable ranged between 1.4 and 2.2 points respectively. CONCLUSION: The potential utility of a single measure such as the VAFS in PD that is reliably correlated with quality of life is consistent with the pursuit to develop clinical tests and measurements that are accessible, easy to use and universally interpretable across health science disciplines. BioMed Central 2018-07-11 /pmc/articles/PMC6040062/ /pubmed/29996887 http://dx.doi.org/10.1186/s12967-018-1554-z Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Chong, Raymond
Albor, Lauren
Wakade, Chandramohan
Morgan, John
The dimensionality of fatigue in Parkinson’s disease
title The dimensionality of fatigue in Parkinson’s disease
title_full The dimensionality of fatigue in Parkinson’s disease
title_fullStr The dimensionality of fatigue in Parkinson’s disease
title_full_unstemmed The dimensionality of fatigue in Parkinson’s disease
title_short The dimensionality of fatigue in Parkinson’s disease
title_sort dimensionality of fatigue in parkinson’s disease
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6040062/
https://www.ncbi.nlm.nih.gov/pubmed/29996887
http://dx.doi.org/10.1186/s12967-018-1554-z
work_keys_str_mv AT chongraymond thedimensionalityoffatigueinparkinsonsdisease
AT alborlauren thedimensionalityoffatigueinparkinsonsdisease
AT wakadechandramohan thedimensionalityoffatigueinparkinsonsdisease
AT morganjohn thedimensionalityoffatigueinparkinsonsdisease
AT chongraymond dimensionalityoffatigueinparkinsonsdisease
AT alborlauren dimensionalityoffatigueinparkinsonsdisease
AT wakadechandramohan dimensionalityoffatigueinparkinsonsdisease
AT morganjohn dimensionalityoffatigueinparkinsonsdisease